Contact Us
Drug Search Results
More Filters [+]

AUR-106

Alternative Names: AUR-106, AUR106, AUR 106
Latest Update: 2024-01-31
Latest Update Note: Clinical Trial Update

Product Description

An oral, small molecule inhibitor of TIGIT and PDL1, developed from Aurigene’s small molecule IO platform. In contrast to antibodies, AUR-106 offers the advantages of ease of combination dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs. (Sourced from: https://www.aurigene.com/pipeline/#proprietary-pipeline)

Mechanisms of Action: TIGIT Inhibitor,PD-L1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aurigene Discovery Technologies
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AUR-106

Countries in Clinic: India

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Kidney Cancer|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
JIVAN

P1

Recruiting

Transitional Cell Carcinoma|Esophageal Cancer|Kidney Cancer|Colorectal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer

2025-05-01

44%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions